Full Press Release Details
Media: Colleen Parr Dekker at (317) 989-7011
Investor Relations: Jim Greffet (317) 383-9935 or greffet_james_f@elanco.com
Expands Executive Team to Lead Company Post Bayer Animal Health Acquisition
Expanded team will enhance Elanco's
customer focus, expertise and agility
as a dedicated animal health company
GREENFIELD, IND. (April 20, 2020) - Elanco Animal
Health Incorporated (NYSE: ELAN) announced today it will expand its existing leadership team, adding a Chief Marketing Officer
and three commercial leaders to its current Executive Committee. The expanded team adds depth and experience to position Elanco
for continued growth.
"With our anticipated addition of Bayer Animal Health,
we're looking to ensure we have the right structure and right leadership in place to support the combined organization and
accelerate the benefits we've already experienced in being singularly focused on animal health," said Jeff Simmons,
president and CEO of Elanco. "Our people have always been Elanco's differentiator. So, in our executive selection process
we focused on identifying people-focused leaders with a proven ability to build, lead and grow an integrated, global business."
The existing Elanco Executive Committee has led the company
through significant transformation while delivering growth and repositioning the business for the next era. Current team members
will remain and will be complemented with key leaders from Bayer Animal Health post-closing, as well as outside expertise that
will help propel the combined company to new levels of leadership. The new leadership structure is designed to speed quality decision
making, draw senior leadership even closer to the customer and accelerate the transformation toward more consumer and brand-centricity.
The new Elanco Executive Committee members include:
Dirk Ehle, current global head of Bayer Animal Health,
will join Elanco as executive vice president and president Elanco Europe at the closing of the Bayer Animal Health acquisition.
Ehle has spent 18 years with Bayer AG in a variety of leadership roles, and the past eight as the leader of Bayer Animal Health.
Under his leadership, Bayer Animal Health focused on driving growth and profitability, strengthening core brands, expanding sales
channel presence while strengthening organization-wide customer focus, increasing R&D productivity and pipeline value.
Joyce Lee, currently president of North America for Bayer
Animal Health, will join Elanco as executive vice president and president US Pet Health and Commercial Operations at acquisition
closing. Since taking her current role in 2016, Lee has accelerated the growth and profitability of the business and increased
North America market share through new market entries, strategic organic growth initiatives and highly successful ecommerce strategies.
Prior to her role at Bayer, Lee held commercial leadership positions at Pfizer, Zoetis and Pharmacia Human Health.
Racquel Harris Mason joins Elanco as executive vice president
and chief marketing officer, effective immediately. Mason brings more than 25 years of general management and consumer marketing
experience developing holistic business strategies, effective communication campaigns and robust innovation pipelines. Her recent
roles include serving as senior vice president at the Coca-Cola Company for the McDonald's Division USA and vice president,
Coca-Cola and Coke Zero brands. Earlier in her career, Mason held positions of increasing responsibility in brand
management with Abbott Laboratories, Johnson & Johnson and Procter & Gamble.
Jos Simas is rejoining Elanco to become executive
vice president US Farm Animal, leaving his position as president of Trouw Nutrition USA. Jos originally joined Elanco in
2000 as Rumensin product manager and held a number of roles of increasing responsibility, including senior director
of Latin America and Global Aquaculture, senior director US Beef Business and area director Central, Eastern Europe, North Africa
"I'm pleased to welcome Dirk, Joyce, Jos
and Racquel to our leadership team. They clearly bring the business expertise and passion for our vision of Food and Companionship
Enriching Life that are hallmarks of our current leadership team," Simmons said. "These new members join a team that
has led Elanco through significant transformation. Together, the executive team will direct the continuation of Elanco's
journey to be a leading, independent animal health company creating significant long-term value for customers, employees, stakeholders
The new leaders join the existing Elanco Executive Committee:
All members of the new executive committee will report to Jeff
Simmons, president and CEO of Elanco Animal Health. Racquel Harris Mason and Jos Simas begin their new roles immediately.
All other role transitions and reporting relationships will be effective and contingent upon close of the Bayer Animal Health acquisition.
(NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food
animals and pets in more than 90 countries. With a 65-year heritage, we rigorously innovate to improve the health of animals and
benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we're
driven by our vision of food and companionship enriching life - all to advance the health of animals, people and the planet. Learn
more at www.elanco.com.
Forward Looking Statement
This press release contains
forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about our expectations
concerning our antitrust filings with the EC and other regulators in connection with our acquisition of the animal health business
of Bayer AG, and reflects Elanco's current belief. Forward-looking statements are based on our current expectations and
assumptions regarding our business and other future conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result,
our actual results may differ materially from those contemplated by the forward-looking statements. For further discussion of
these and other risks and uncertainties, see Elanco's most recent filings with the United States Securities and Exchange
Commission. Except as required by law, Elanco undertakes no duty to update forward-looking statements to reflect events after
the date of this release.